Camden National Corporation
NASDAQ:CACBanks - Regional
+$0.02 today
- Market cap
- $981.28M
- Beta
- 0.56
- P/E (TTM)
- 10.9
- EPS (TTM)
- $4.70
- Dividend yield
- 3.27%
Volume 0.06M
Average 0.10M
CAC Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Camden National CorporationNASDAQ: CAC
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How CAC compares with its peers on the latest reported figures
- CAC's LTM Mar 2026 research & development of $0 is the highest of the 11 companies compared; the peer median is $0.
- Research & development amounts to 0.0% of revenue for CAC, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CAC) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for CAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 193.91M | 208.89M | 250.32M | 289.72M | 367.34M |
| Cost of Revenue | 7.86M | 29.59M | 94.25M | 117.61M | 136.72M |
| Gross Profit | 186.05M | 179.29M | 156.07M | 172.11M | 230.62M |
| Gross Margin | 95.9% | 85.8% | 62.3% | 59.4% | 62.8% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 61.01M | 62.02M | 60.01M | 64.07M | 59.72M |
| Operating Expenses | 99.41M | 102.25M | 102.24M | 106.65M | 149M |
| Depreciation & Amortization | 4.36M | 4.12M | 3.96M | 3.87M | 9.92M |
| EBITDA | 91M | 81.16M | 57.8M | 69.33M | 91.54M |
| EBITDA Margin | 46.9% | 38.9% | 23.1% | 23.9% | 24.9% |
| Operating Income | 86.64M | 77.05M | 53.84M | 65.46M | 81.62M |
| Operating Margin | 44.7% | 36.9% | 21.5% | 22.6% | 22.2% |
| Interest Income | 148.48M | 172.79M | 226.25M | 249.56M | 320.66M |
| Interest Expense | 11.05M | 25.09M | 93.98M | 117.1M | 117.4M |
| Other Income / Expenses | 0 | 0 | 0 | 0 | (2.97M) |
| Income Before Tax | 86.64M | 77.05M | 53.84M | 65.46M | 78.66M |
| Pre-Tax Margin | 44.7% | 36.9% | 21.5% | 22.6% | 21.4% |
| Income Tax Expense | 17.63M | 15.61M | 10.45M | 12.46M | 13.5M |
| Net Income | 69.01M | 61.44M | 43.38M | 53M | 65.16M |
| Net Margin | 35.6% | 29.4% | 17.3% | 18.3% | 17.7% |
| EPS (Basic) | 4.62 | 4.18 | 2.98 | 3.63 | 3.85 |
| EPS (Diluted) | 4.60 | 4.17 | 2.97 | 3.62 | 3.84 |
| Weighted Avg Shares | 14.9M | 14.64M | 14.56M | 14.58M | 16.84M |
| Weighted Avg Shares (Diluted) | 14.97M | 14.7M | 14.61M | 14.63M | 16.96M |
Camden National Corporation
NASDAQ:CAC
Intrinsic Alpha fair value
Locked
Current Price
$58.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.